-
Je něco špatně v tomto záznamu ?
Implementing reversed-phase and hydrophilic interaction liquid chromatography into the characterization of DTPA-ramucirumab conjugate before radiolabeling
DK. Naplekov, P. Bárta, F. Trejtnar, H. Sklenářová, J. Lenčo
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články
- MeSH
- chelátory MeSH
- chromatografie kapalinová metody MeSH
- chromatografie s reverzní fází * metody MeSH
- hydrofobní a hydrofilní interakce MeSH
- imunokonjugáty * MeSH
- kyselina pentetová MeSH
- Publikační typ
- časopisecké články MeSH
Radioimmunoconjugates represent a promising class of therapeutics and diagnostics. The characterization of intermediate chelator-antibody products, i.e., without the radionuclide, is frequently omitted, bringing significant uncertainty in the radioimmunoconjugate preparation. In the present study, we explored the utility of reversed-phase (RPLC) and hydrophilic interaction (HILIC) liquid chromatography with UV detection to characterize ramucirumab stochastically conjugated with p-SCN-Bn-CHX-A"-DTPA chelator (shortly DTPA). The conjugation was well reflected in RPLC chromatograms, while chromatograms from HILIC were significantly less informative. RPLC analyses at the intact level confirmed that the conjugation resulted in a heterogeneous mixture of modified ramucirumab. Moreover, the RPLC of DTPA-ramucirumab confirmed heterogeneous conjugation of all subunits. The peptide mapping did not reveal substantial changes after the conjugation, indicating that most parts of ramucirumab molecules remained unmodified and that the DTPA chelator was bound to various sites. Eventually, the RPLC method for analysis of intact ramucirumab was successfully applied to online monitoring of conjugation reaction in 1 h intervals for a total of 24 h synthesis, which readily reflected the structural changes of ramucirumab in the form of retention time shift by 0.21 min and increase in peak width by 0.22 min. The results were obtained in real-time, practically under 10 min per monitoring cycle. To the best of our knowledge, our study represents the first evaluation of RPLC and HILIC to assess the quality of intermediates during the on-site preparation of radioimmunoconjugates prior to radiolabeling.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23016074
- 003
- CZ-PrNML
- 005
- 20231026110501.0
- 007
- ta
- 008
- 231013s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.jpba.2023.115615 $2 doi
- 035 __
- $a (PubMed)37566949
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Naplekov, Denis K $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Akademika Heyrovskeho 1203/8, 500 05 Hradec Kralove, Czech Republic
- 245 10
- $a Implementing reversed-phase and hydrophilic interaction liquid chromatography into the characterization of DTPA-ramucirumab conjugate before radiolabeling / $c DK. Naplekov, P. Bárta, F. Trejtnar, H. Sklenářová, J. Lenčo
- 520 9_
- $a Radioimmunoconjugates represent a promising class of therapeutics and diagnostics. The characterization of intermediate chelator-antibody products, i.e., without the radionuclide, is frequently omitted, bringing significant uncertainty in the radioimmunoconjugate preparation. In the present study, we explored the utility of reversed-phase (RPLC) and hydrophilic interaction (HILIC) liquid chromatography with UV detection to characterize ramucirumab stochastically conjugated with p-SCN-Bn-CHX-A"-DTPA chelator (shortly DTPA). The conjugation was well reflected in RPLC chromatograms, while chromatograms from HILIC were significantly less informative. RPLC analyses at the intact level confirmed that the conjugation resulted in a heterogeneous mixture of modified ramucirumab. Moreover, the RPLC of DTPA-ramucirumab confirmed heterogeneous conjugation of all subunits. The peptide mapping did not reveal substantial changes after the conjugation, indicating that most parts of ramucirumab molecules remained unmodified and that the DTPA chelator was bound to various sites. Eventually, the RPLC method for analysis of intact ramucirumab was successfully applied to online monitoring of conjugation reaction in 1 h intervals for a total of 24 h synthesis, which readily reflected the structural changes of ramucirumab in the form of retention time shift by 0.21 min and increase in peak width by 0.22 min. The results were obtained in real-time, practically under 10 min per monitoring cycle. To the best of our knowledge, our study represents the first evaluation of RPLC and HILIC to assess the quality of intermediates during the on-site preparation of radioimmunoconjugates prior to radiolabeling.
- 650 12
- $a chromatografie s reverzní fází $x metody $7 D056148
- 650 _2
- $a chromatografie kapalinová $x metody $7 D002853
- 650 _2
- $a hydrofobní a hydrofilní interakce $7 D057927
- 650 12
- $a imunokonjugáty $7 D018796
- 650 _2
- $a chelátory $7 D002614
- 650 _2
- $a kyselina pentetová $7 D004369
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Bárta, Pavel $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Biophysics and Physical Chemistry, Akademika Heyrovskeho 1203/8, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Trejtnar, František $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Pharmacology and Toxicology, Akademika Heyrovskeho 1203/8, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Sklenářová, Hana $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Akademika Heyrovskeho 1203/8, 500 05 Hradec Kralove, Czech Republic
- 700 1_
- $a Lenčo, Juraj $u Charles University, Faculty of Pharmacy in Hradec Kralove, Department of Analytical Chemistry, Akademika Heyrovskeho 1203/8, 500 05 Hradec Kralove, Czech Republic. Electronic address: lenco@faf.cuni.cz
- 773 0_
- $w MED00002894 $t Journal of pharmaceutical and biomedical analysis $x 1873-264X $g Roč. 235, č. - (2023), s. 115615
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37566949 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20231013 $b ABA008
- 991 __
- $a 20231026110455 $b ABA008
- 999 __
- $a ok $b bmc $g 1999915 $s 1202436
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 235 $c - $d 115615 $e 20230731 $i 1873-264X $m Journal of pharmaceutical and biomedical analysis $n J Pharm Biomed Anal $x MED00002894
- LZP __
- $a Pubmed-20231013